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Abstract
Background: Gastrointestinal (GI) cancer is frequently diagnosed in people of working age, and many GI cancer
patients experience work-related problems. Although these patients often experience difficulties returning to work,
supportive work-related interventions are lacking. We have therefore developed a tailored work-related support
intervention for GI cancer patients, and we aim to evaluate its cost-effectiveness compared with the usual care
provided. If this intervention proves effective, it can be implemented in practice to support GI cancer patients after
diagnosis and to help them return to work.
Methods/Design: We designed a multicentre randomized controlled trial with a follow-up of twelve months. The
study population (N = 310) will include individuals aged 18–63 years diagnosed with a primary GI cancer and
employed at the time of diagnosis. The participants will be randomized to the intervention or to usual care. ‘Usual
care’ is defined as psychosocial care in which work-related issues are not discussed. The intervention group will
receive tailored work-related support consisting of three face-to-face meetings of approximately 30 min each. Based
on the severity of their work-related problems, the intervention group will be divided into groups receiving three
types of support (A, B or C). A different supportive healthcare professional will be available for each group: an
oncological nurse (A), an oncological occupational physician (B) and a multidisciplinary team (C) that includes an
oncological nurse, oncological occupational physician and treating oncologist/physician. The primary outcome
measure is return to work (RTW), defined as the time to a partial or full RTW. The secondary outcomes are work
ability, work limitations, quality of life, and direct and indirect costs.
Discussion: The hypothesis is that tailored work-related support for GI cancer patients is more effective than usual
care in terms of the RTW. The intervention is innovative in that it combines oncological and occupational care in a
clinical setting, early in the cancer treatment process.
Trial registration: METC protocol number NL51444.018.14/Netherlands Trial Register number NTR5022. Registered
6 March 2015.
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Background
Patients with gastrointestinal (GI) cancer experience
work-related problems at the time of diagnosis [1]. In gen-
eral, cancer survival rates have been improving in recent
years due to early detection via screening programmes
and continuous improvements in treatment [2, 3]. The
burden of the disease itself and the treatment not only
negatively affects quality of life [4–6] in all its aspects, but
also work participation [7], with the additional financial
consequences this brings [8, 9]. Work participation is
becoming increasingly important in today’s ageing society,
meaning that the incidence of cancer in patients of work-
ing age is also increasing. Furthermore, the raising of the
retirement age is expected to bring an additional increase
in the number of cancer survivors in the working
population.
It is important that cancer patients are able to return to
work (RTW), because having a fulfilling work life is associ-
ated with a higher quality of life [10, 11] and provides
much-needed income [12]. Most cancer survivors want to
resume work after treatment, but regrettably, not all survi-
vors are able to do so, because they experience various dif-
ficulties and treatment-related factors [1, 13, 14], or even
become unemployed [15]. In addition to diagnosis and
treatment, patients have to deal with physical, emotional
and social problems such as fatigue, pain, cognitive defi-
cits, anxiety and depression. These can impair social func-
tioning and affect the patients’ ability to RTW [15, 16].
Relatively few studies have assessed the employment sta-
tus of patients with GI cancer [17, 18] compared to well-
studied diagnoses such as breast cancer [19, 20]. Besides
work-related problems due to cancer, GI cancer patients
can be confronted with specific GI cancer-related problems,
such as eating, defecation or stoma problems, which can
interfere with their work and for which they need support.
Work-related problems are experienced both at the time of
diagnosis and during treatment, but no work-related sup-
port (in the form of interventions) is provided nowadays in
curative settings. Earlier research has shown that patients
appreciate receiving information on their RTW in the early
stages of cancer treatment [1, 21, 22]. It is therefore essen-
tial to have an in-hospital-based care programme to sup-
port the RTW process. Moreover, work-related problems
can vary in severity, meaning that any such intervention
should provide tailored support.
We have developed a tailored work-related support
intervention for GI cancer patients. We aim to evalu-
ate the cost-effectiveness of the tailored work-related
support intervention as compared with usual care. If
this intervention proves effective, it can be imple-
mented in practice to support GI cancer patients,
starting at diagnosis, during treatment and in the
period after diagnosis and treatment to help them
RTW.
Objective
The objective of this paper is to present the design of a
study that aims to evaluate the tailored work-related
support intervention in terms of cost-effectiveness.
Methods/Design
This study will take the form of a two-armed non-blinded
multicentre randomized controlled trial (RCT), with a
follow-up of twelve months (see Fig. 1). We will compare
the tailored work-related support intervention with the
control group receiving the usual care, which takes the
form of standard psycho-oncological care. Data will be
gathered using questionnaires at baseline, three, six, nine
and twelve months. The CONSORT statement was used
to report the design of this study [23].
The Medical Ethical Committee of the Academic Medical
Center Amsterdam, the Netherlands, approved the study.
The local medical ethics committees of the participation
hospitals gave positive advice on the local feasibility of the
study. The participating hospitals are Albert Schweitzer
hospital Dordrecht, Amphia hospital Breda, Gelre hospitals
location Apeldoorn and Zuthpen, Martini hospital Gro-
ningen, the University Medical Center Groningen, Meander
Medical Center Amersfoort, OLVG hospital Amsterdam
and the Medical Center Alkmaar.
METC protocol number NL51444.018.14
Trial registration number NTR5022 registered on 6
March 2015.
Study population
The study population (N= 310) will include individuals
aged between 18 and 63 years, with a primary diagnosis
of GI cancer (oesophagus, stomach, liver, pancreas,
biliary, small intestine, colon or rectum cancer), treated
with curative intent (no study restrictions for type of
treatment), employed at the time of diagnosis (including
self-employment) and being on sick leave as a result of
work-related problems due to the cancer diagnosis. The
exclusion criteria are: 1) patients who are unable to
speak, read or write Dutch sufficiently; 2) patients who
have a severe mental disorder or other severe co-
morbidity; and 3) patients who are receiving primary
treatment at another hospital.
Recruitment of participants
Eligible patients will be recruited between May 2015 and
July 2016. GI cancer patients will be asked to participate
at the hospital where they are receiving their treatment.
The oncologist or oncological nurse will check each
patient’s eligibility by assessing the inclusion and exclusion
criteria. During their first visit to the hospital where they
are being treated, patients will be informed about the
study by their oncologist or oncological nurse. The
oncologist or oncological nurse will then provide the
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patient with a brief explanation of the study and the
patient will be asked whether the researcher may contact
them by telephone. If the patient agrees, he or she will
sign a specific informed consent form for telephone con-
tact. The patient will be given a folder with an information
leaflet, contact information and the informed consent
form. If the patient immediately decides not to participate,
the oncologist or oncological nurse asks the patient
whether he/she wants to provide a reason for not partici-
pating, but the patient is not obliged to do so. If the
patient has given their informed consent to be contacted
by telephone, the researcher will phone the patient within
one week. A meeting (in person or by telephone) will be
scheduled at in which outstanding questions relating to
the study can be answered, and at which the informed
consent form will be signed in the presence of the re-
searcher before the patient can participate in the
study (which is known as GIRONA: GastroIntestinal
cancer patients Receiving Occupational support Near
and After diagnosis). The patient subsequently re-
ceives the baseline questionnaire, either on paper or
digitally (depending on their preference). If they do
not return the baseline questionnaire, the researcher









1st meeting before 
start of treatment 
T1: 3 months 2nd meeting max. 




3rd meeting max. 
6-9 months after 
1st meeting 
Randomization
Patient with primary GI cancer diagnosis, 18-63 years, treated with curative 
intent, employed at the time of diagnosis and on sick leave
INFORMED CONSENT
Fig. 1 Flow chart of RCT, design of the GIRONA study
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Participants can leave the study at any time, for any rea-
son, without any consequences for their normal cancer
care. They will be asked about their reason for withdrawal,
but they will not be obliged to answer this question.
Randomization
When the researcher has received the baseline question-
naire, the patient will be randomized to 1) the interven-
tion group that will receive tailored work-related support,
or 2) the control group that will receive care as usual. A
computerized randomization programme ALEA [24] will
be used to do this. As patients differ between the partici-
pating hospitals in terms of diagnosis, demographic fac-
tors and age, and because these factors are important
prognostic factors for RTW [25], randomization will be
stratified for gender, age (age groups: 18–54 and 55–63
years) and hospital, so as to prevent bias due to unequal
randomization. Minimization will be applied to equalize
group sizes. The patients, healthcare professionals and
researchers will not be blinded for the group assignment.
The intervention: tailored work-related support
The intervention consists of three individual meetings
between a patient and a healthcare professional within
the clinical setting. As work-related problems differ in
severity, the intervention will be divided into three types
of support, namely: support A, support B and support C.
In an earlier study (published separately) with an
expert panel consisting of physicians, oncological nurses,
(oncological) occupational physicians, social workers and
patients, a decision diagram was drawn up that, based
on a list of factors from the literature, refers the patient
to one of the three types of support (A, B or C) for the
tailored work-related support intervention (see Table 1).
These factors have been added to the patients’ baseline
questionnaire (T0). Based on a participant’s answers to
this baseline questionnaire and the decision diagram, the
researcher will refer the participant to the tailored types
of support A, B or C.
The three support types also differ in terms of the
healthcare professional providing the supportive care.
The intervention will be implemented by an oncological
nurse in support type A, by an oncological occupational
physician (specialized in oncological patients’ RTW) in
support type B, and by a multidisciplinary team (includ-
ing, at a minimum, an oncological nurse, the treating
physician and the oncological occupational physician) in
support type C. The main differences in the three types
of support within the intervention are thus the factors
for which a patient is referred to support type A, B or C,
and the healthcare professionals who provide the sup-
port (Table 1).
Before the start of the study, the oncological nurses who
will give the work-related support in the intervention
participate in a training session lasting 2.5 h. This training
session will consist of an informative part on the GIRONA
study, the intervention and the importance of work for
patients, and training on the rights and obligations of em-
ployees on sick leave in the Dutch social security system.
Furthermore, work-related problems due to cancer and
cancer treatment will be discussed, such as the feasibility
of continuing to work during treatment, the factors that
have an impact on the RTW, and the extent to which
patients are open about their cancer with colleagues and
employers. In addition, the checklist forms, which serve as
a guideline for conversation, are discussed and practised
with reference to a case.
The training session is given by the researcher [AZ],
who has clinical experience as a nurse and conducts re-
search on cancer and work. The training session includes
elements that were used in previous research, in which a
work-directed intervention was developed consisting of
four meetings with a nurse and a meeting with the occu-
pational physician and supervisor to make a RTW plan
[26]. The oncological occupational physicians are special-
ized in supporting patients with cancer who encounter
work-related problems. They followed an accredited train-
ing course on ‘basic training for oncological occupational
physicians’, given by the Netherlands School of Public and
Occupational Health (NSPOH) in Amsterdam, the
Netherlands.
The aim of the first meeting is to inform patients about
the importance of work during and after treatment, to
identify any work-related problems, and to make a plan
for the RTW (Table 1). The meeting will be scheduled
before the start of the treatment and will take the form
of an individual face-to-face meeting lasting approxi-
mately 30 min.
The second meeting aims to inform and evaluate the
goals of the first meeting. This meeting will be scheduled
after the first meeting, in consultation with the patient
and the supporting healthcare professional (depending
on the diagnosis/treatment and preferences of the
patient). It will take place no more than three to six
months after the first meeting. It will take the form of
an individual face-to-face meeting and last about 30 min
(Table 1). At the end of the meeting, the healthcare pro-
fessional will evaluate whether the work-related support
being provided is sufficient (on the basis of the decision
diagram and the patient’s answers). If the support proves
to be insufficient, the type of support will be adjusted.
The third meeting will consider the same issues as the
second meeting: evaluating the goals of the first and sec-
ond meetings. This meeting will also be scheduled at the
request of the patient and/or the supporting healthcare
professional at the second meeting, depending on diagno-
sis/treatment and the preferences of the patient, and in a
maximum of six to nine months after treatment (Table 1).
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In the support C-type intervention (multidisciplinary
meeting), the oncological occupational physician will
first hold a face-to-face meeting with the patient before
the multidisciplinary meeting. The team will subse-
quently confer to discuss the outcomes identified by the
oncological occupational physician with respect to RTW
possibilities and restrictions. The oncological occupa-
tional physician will lead the multidisciplinary team con-
sultation and is designated to provide the patient with
feedback in a further face-to-face or telephone meeting.
Care as usual
Care as usual in the clinical setting involves standard
psychosocial care provided by the oncological nurse dur-
ing regular appointments. In most cases, this means that
the patient’s perceptions after treatment and possible
treatment-related problems or complications are dis-
cussed. However, RTW, work-related problems or
treatment-induced work problems are not routinely dis-
cussed in this form of psychosocial care.
Sample size
The calculation of the sample size is based on two earl-
ier studies, because no recent data are available on the
RTW of GI cancer patients from clinical patient cohorts.
Data from 2005 on 220 GI cancer patients, provided by
a large occupational health service in the Netherlands,
show that two years after diagnosis, 63 % of patients had
returned to work full-time [27]. Based on these data, it
is hypothesized that the percentage of 63 % RTW in GI
cancer patients is the maximum result of ‘care as usual’.
In a study by Nieuwenhuijsen [28], an intervention
Table 1 Overview of tailored support (A, B and C), depending on type of work-related problems experienced
Healthcare
professional







• Uncertainty about the future
• Lack of support from family
and friends
• Lack of support in work environment
• Neuropsychological symptoms
• Occurrence of side effects that
prevent patient from doing current
work




Combination of the following factors:
Medical complications—fatigue—stage of
cancer—type of cancer—perception of




• Discuss restrictions on work
due to cancer
• Inform patient about the
importance of work
• Feasibility of continuing to
work during treatment
• Patient’s point of view on work
• Plan to RTW or sustain work
• Discuss restrictions on work due to
cancer
• Inform patient about the importance
of work
• Feasibility of continuing to work
during treatment
• Patient’s point of view on work
• Plan to RTW or sustain work
• Advice on workload/planning
working hours/tasks, etc.
• Preliminary interview, occupational
physician and patient
• Multidisciplinary team consultation
• Occupational physician provides feedback
to patient
• Discuss restrictions on work due to cancer
• Inform patient about the importance of work
• Feasibility of continuing to work during
treatment
• Patient’s point of view on work
• Plan to RTW or sustain work





• Discuss contact with work
environment
• Already resumed work or still
working
• Barriers to RTW
• Discuss key decision-points within
the process of reporting sick leave
(legal obligations)
• Evaluate aims first meeting
• Discuss contact with work
environment
• Already resumed work or still
working
• Barriers to RTW
• Discuss key decision-points within
the process of reporting sick leave
(legal obligations)
• Evaluate aims first meeting
• Discuss contact with work environment
• Already resumed work or still working
• Barriers to RTW
• Discuss key decision-points within the
process of reporting sick leave
(legal obligations)
• Evaluate aims first meeting
Third meeting
(if indicated)
Repeat matters discussed in second
meeting
• Discuss contact with work
environment
• Already resumed work or still
working
• Barriers to RTW
• Discuss key decision-points within
the process of reporting sick leave
(legal obligations)
• Evaluate aims first and second
meeting
Repeat matters discussed in second
meeting
• Discuss contact with work
environment
• Already resumed work or still
working
• Barriers to RTW
• Discuss key decision-points within
the process of reporting sick leave
(legal obligations)
• Evaluate aims first and second
meeting
Repeat matters discussed in second meeting
• Discuss contact with work environment
• Already resumed work or still working
• Barriers to RTW
• Discuss key decision-points within the
process of reporting sick leave
(legal obligations)
• Evaluate aims first and second meeting
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group of 35 radiotherapy patients received a supportive
work-related intervention in a hospital. RTW was mea-
sured between the end of curative treatment and the
first day of (partial) work resumption. This was found to
be 89 % after twelve months. The median time between
enrolment and the end of treatment was 42 days. Earlier
studies at the AMC show that the percentage of patients
that RTW in the first 42 days is around 8 % [29, 30].
The RTW for the intervention group was therefore set
at 89 %–8 % = 81 %.
The sample size is calculated using the Power and
Sample Size Calculation program nQuery Advisor 7.0. A
power of 80 % and a p value of <0.05 indicated that we
should include a total of 216 patients, with a follow-up
of twelve months, to indicate a difference of 81 % (inter-
vention) versus 63 % RTW (care as usual). Allowing for
a 20 % loss to follow-up and a 10 % one-year mortality
rate, 309 patients should be included.
Outcome measures and prognostic factors
Data on the primary and secondary outcomes, as well as
prognostic factors such socio-demographic factors (i.e. age,
gender, level of education), disease-related factors and
work-related factors, will be gathered using five question-
naires: baseline (T0) and three (T1), six (T2), nine (T3) and
twelve (T4) months after baseline. It will take approxi-
mately 30 min to complete a questionnaire. The primary
outcome measure is RTW, defined as the time to a partial
or full RTW, and measured as the number of calendar days
between the first day of sick leave and the first day at work.
The patient must have returned to work (part-time or full-
time) for at least four successive weeks (independent of the
number of contract hours). The secondary outcome param-
eters are work ability, work limitations, quality of life, RTW
(yes/no) and direct/indirect costs.
Effect evaluation
The effectiveness of the study will be determined on the
basis of the primary outcome RTW and the secondary
outcomes work ability, work limitations and quality of
life, assessed at a long-term follow-up at twelve months.
RTW will be based on the patients’ self-reporting in the
questionnaires (T0-T4).
Work ability will be assessed with reference to the first
three questions of the Work Ability Index (WAI) [31],
using a ten-point scale. These questions concern an evalu-
ation of a patient’s current work ability compared to their
lifetime best ability, and their current physical and mental
work ability with respect to their job demands. Higher
scores indicate a higher level of work ability (0 means not
currently able to work at all, and 10 means work ability at
its best). The index has been assessed as having good
levels of reliability and validity [32].
Work limitations will be measured with the Work
Limitation Questionnaire (WLQ) [33], using a five-point
scale. This questionnaire evaluates work disability and
productivity (loss) in people with health problems. It
consists of four sub-scales with 25 items: work schedul-
ing, physical demands, mental/social demands and out-
put demands. The scale ranges from 0 to 100, with
higher scores indicating more work limitations over the
previous two weeks (0 means never limited and 100
means limited all of the time). The English version of
the WLQ has been shown to be valid and reliable when
used for cancer survivors [34]. The WLQ questionnaire
has been translated into Dutch and is valid and reprodu-
cible at group level among cancer survivors [35].
Quality of life will be measured with two question-
naires; 1) the SF12 [36, 37], to compare the study partic-
ipants with the normal population, and 2) the EORTC
QLQ-C30 [38], to compare the quality of life of the
study participants diagnosed with GI cancer with that of
patients with other cancer diagnoses. These question-
naires provide insight in the participants’ feelings about
their health and their ability to carry out their usual
activities.
The SF12 consists of twelve items, providing scales for
physical and mental health. Questions refer to the pa-
tient’s functional status, including their physical and so-
cial functioning and physical and emotional constraints
and their general view of their own health. The physical
and mental health scores are calculated using the scores
of twelve questions. The questionnaire has a range from
0 to 100 (0 means the lowest level of health measured
by the scales, and 100 indicates the highest level of
health).
The EORTC QLQ-C30 contains 30 items, including
five functional scales, three symptom scales, a global
health status/Quality of Life scale and six single items.
Scores range from 0 to 100. A higher score represents a
higher (better) level of functioning or a higher (worse)
level of symptoms.
Process evaluation
The process of the intervention will be evaluated with
the following parameters: number of consultations
within the intervention, number of consultations with
other work-related support interventions, and partici-
pant satisfaction, measured with the self-reporting ques-
tionnaires. Participants may use any co-interventions
that they wish to use; there will be no restrictions. In
order to evaluate this, participants in both the interven-
tion and the control groups will be asked in the self-
reporting questionnaires about the type and number of
co-interventions they received.
The content of the consultation, the number of referrals
to the other types of support within the intervention, the
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evaluation (using the decision diagram) of whether the
work-related support is sufficient and the health profes-
sionals’ general perceptions of and satisfaction with the
intervention are measured using the protocol forms,
which are completed during the meeting with the patient.
Economic evaluation
A cost-effectiveness analysis (CEA) will be performed,
taking a societal perspective. The economic evaluation
will cover work-related costs to society and the cost of
healthcare for the patients themselves and for their
employers. The following costs (payment discipline for
intervention meetings/nurse training/days of patient’s
hospital admission/patients’ income and work adjust-
ments) will be measured for the intervention group as
well as for the control group.
Indirect costs, including absenteeism (determined as
the total number of days of sick leave from the first day
of sick leave at baseline until follow-up), lost earnings
(determined as the difference in income between base-
line and follow-up) and work productivity (measured
using the Work Limitation Questionnaire), will be taken
into account and obtained with the patients’ question-
naires (T0-T4). Direct costs such as the duration of the
intervention (in minutes) for each patient by the health-
care professional will be presented. The healthcare pro-
fessionals will record the duration of each meeting.
Prognostic factors
The prognostic factors include age, gender, marital status
(married/single/cohabiting/widowed/divorced), education
(seven categories), diagnosis (primary GI cancer diagnosis:
oesophagus, stomach, liver, pancreas, biliary, small intestine,
colon or rectum), treatment type (surgery, radiotherapy,
chemotherapy, hormonal therapy, other) and treatment
duration assessed with the self-reporting questionnaires.
Fatigue is measured using the Multidimensional Fatigue
Inventory questionnaire (MFI) [39], with 20 items divided
into five sub-scales: general fatigue, physical fatigue,
reduced activity, reduced motivation and mental fatigue.
The sub-scale scores range from 4 to 20; a higher (implies
20) score indicates greater fatigue. Depression is measured
using the scale developed by the Centre for Epidemiologic
Studies for Depression (CES-D) [40], scored with 20 items.
The scores range from 0 to 60; a higher (implies 60) score
indicates greater depressive symptoms weighted for the past
week. Cognitive functioning is measured with the Cognitive
Symptom Checklist-Work, Dutch Version (CSC-W DV),
containing 19 items, with the sub-scales for working mem-
ory and executive function. Scores range from 0 to 100,
with higher scores indicating more cognitive symptoms
(i.e., more limitations) in the work context. This question-
naire has been translated and a customized version of the
Cognitive Symptom Checklist-Work (CSC-W) [41] valid-
ation article will be published.
Descriptive factors
The descriptive factors include breadwinner status (yes/no),
job position (permanent contract/temporary contract/tem-
porary worker/self-employed/other), employment status
(employed/unemployed/self-employed/pension), years in
current position, and company size (large 100 ≥ employees/
medium-sized 10–100 employees/small 1–10 employees,
or not applicable; self-employed), which will be assessed
with the self-reporting questionnaires. The stage of cancer
will be assessed from the patient’s medical records. Further-
more, the Perception and Judgement of Work (VBBA) [42]
questionnaire will be used, with the sub-scale ‘physical
workload’ containing seven items. The scores range from 0
to 21; a higher score indicates a higher physical workload.
The importance of work is measured with a Visual
Analogue Scale (VAS-scale), with a line running from 0
(not important) to 10 (most important).
Statistical analysis
All analyses will be conducted in accordance with the
intention-to-treat (ITT) principle. After randomization,
participants will be labelled with a research code consisting
of a unique number. This unique number will be used for
the data analysis, to guarantee blind analysis of the data by
the researcher. Baseline data and data regarding primary
and secondary outcomes will be presented using descriptive
statistics. Differences in baseline data between the interven-
tion and control group will be assessed using Student’s
t-test for continuous data and the χ2-test for categorical
data. A p-value ≤ 0.05 will be considered statically
significant.
Primary study parameter
For the primary outcome measure (RTW), the number
of days until RTW (either full or partial) will be analysed
using a Kaplan-Meier survival method. The patients who
dropped out of the study will be censored. The differ-
ences between the intervention and the control group
will be tested using a log rank test. If significant differ-
ences between the intervention and control groups are
found with regard to the prognostic variables, the out-
come variable RTW will be adjusted for these variables
in a multivariate Cox regression analysis. In addition to
the ITT analysis aimed at ‘all—cause return to work’, the
analysis will be performed excluding those patients who
died during follow-up and those who have a life expect-
ancy of less than a few months, because they will not
RTW.
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Secondary study parameters
The relative risk and 95 % confidence interval for returning
to work (either full or partial) at twelve months of follow-
up will be calculated for the intervention group versus the
control group. Longitudinal multilevel analysis will be used
to examine differences between the intervention and con-
trol groups with regard to the secondary outcomes (quality
of life, work ability and work limitations).
Economic evaluation
The direct and indirect costs will be calculated for each
participant. Using bootstrapping, mean differences in dir-
ect, indirect, and total costs will be calculated between the
control group and the intervention group [43]. Incremen-
tal cost-effectiveness ratios will be calculated by assessing
the ratio of the differences in costs between the interven-
tion and control groups to the differences in RTW rates
between the groups.
Discussion
The aim of this study is to evaluate the cost-effectiveness
of a tailored work-related support intervention for GI can-
cer patients, which will be carried out as an RCT compared
with usual care.
Although some GI cancer patients indicate that they
would prefer to continue working even during treatment
[1, 22, 44], at present there are no effective work-related
interventions for GI cancer patients early in the treat-
ment process [17, 21]. Previous research suggests that
interventions should be developed to support patients
with work-related problems [44, 45]. The tailored inter-
vention described in this study will provide work-related
support at an early stage of the cancer diagnosis and
treatment process. In the course of the tailored work-
related support intervention, patients will receive indi-
vidualized support based on their specific work-related
problems.
The nurses in this study will receive training prior to the
start of the GIRONA study, to enable them to give sup-
portive care to patients in the ‘support A’ intervention
group. It is therefore conceivable that bias might occur in
this study, because the nurses will become aware of the
importance of work for cancer patients. These nurses also
provide the usual care in the control group. Due to the
nurses’ awareness of the importance of work, there is a
possibility that the trained nurses might unintentionally
incorporate their understanding of the importance of
work into the counselling sessions they provide for pa-
tients receiving the usual care. This could mean that pa-
tients in the control group receive work-related advice, or
that the nurses influence the patient’s self-efficacy, with
the effect that the patients themselves start searching for
work-related interventions. To monitor this, patients will
be asked in the questionnaires whether they have attended
additional work-related care sessions. There is a risk, how-
ever, that because of the mechanisms described above, the
contrast between the intervention group and the control
group could be diminished.
Multidisciplinary cooperation within the clinical setting
is centred around the patient; this is important when there
are complex problems at hand, including work-related
problems. For support type C, a multidisciplinary team
meeting forms part of the intervention. With this type of
support, multiple forms of expertise are combined for the
patient’s benefit, in order to prevent contradictory advice
from being given to the patients. Providing tailored work-
related support within a clinical setting makes it easier for
the different healthcare professionals to be in contact with
each other. Previous research has shown that information-
sharing between healthcare professionals is an essential
aspect of effective transition in cancer care [46].
The fact that the oncological occupational physician is
working within a clinical setting will ensure that cooper-
ation between the oncological occupational physician
and primary care is optimized. This is important, as both
are key to a successful RTW.
This study will provide us with information about the
effectiveness of tailored work-related support on the
RTW during the clinical process, as compared with pa-
tients who get the usual care. The intervention will bring
a new focus to occupational revalidation early in the
treatment process. To date, questions about the RTW
have not routinely been addressed early in the treatment
process.
If this intervention proves effective, it can be imple-
mented in practice to support GI cancer patients,
starting at the moment of diagnosis and in the treat-
ment process, to provide them with support on
work-related problems and enhance the RTW. The
intervention is innovative in that oncological and
occupational care are combined in a clinical setting
in the cancer treatment process. The subsequent step
will be to apply the intervention to other cancer
diagnoses.
The results of the GIRONA study will be available in
2017.
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